BioMed X and Novo Nordisk Collaborate to Revolutionize Oral Peptide Drug Delivery
TL;DR
BioMed X and Novo Nordisk's collaboration offers a competitive edge in developing oral peptide delivery technologies, potentially revolutionizing treatment accessibility and efficacy.
The project focuses on creating oral formulation technologies for prolonged peptide retention in the gut, aiming to enhance drug absorption and bioavailability through innovative research.
This partnership aims to improve patient compliance and quality of life by making peptide-based therapeutics more accessible and effective through advanced oral delivery methods.
A groundbreaking collaboration between BioMed X and Novo Nordisk seeks to tackle the challenge of oral peptide delivery, promising a leap forward in medical treatment options.
Found this article helpful?
Share it with your network and spread the knowledge!
BioMed X, an independent biomedical research institute, and Novo Nordisk, a global healthcare leader, have announced a collaborative effort to overcome one of the most pressing challenges in drug development: the oral delivery of therapeutic peptides. This partnership, centered around the project 'Prolonged Retention of Oral Peptide Formulations in the Gut', seeks to develop new technologies that enhance the absorption and bioavailability of peptide-based drugs by ensuring their prolonged retention in the lower small intestine.
The initiative is a response to the limitations faced by current oral peptide formulations, which suffer from low intestinal permeability and rapid gastrointestinal transit. By focusing on site-specific, prolonged retention of tablets or capsules, the research aims to facilitate continuous release and efficient absorption of peptides, thereby improving patient compliance without compromising gastrointestinal safety.
The research team for this project will be based at BioMed X in Heidelberg, Germany, and is open to early-career scientists from around the world. Interested researchers can submit their proposals through the BioMed X Career Space before October 12, 2025.
Dr. Christian Tidona, CEO of BioMed X, expressed enthusiasm about the collaboration, highlighting its potential to make peptide drugs like GLP-1 receptor agonists orally available, significantly impacting patients' lives. Stephen Buckley, Scientific Vice President at Novo Nordisk, emphasized the company's commitment to pushing the boundaries of science through both internal and external innovation, underscoring the project's potential to bring about groundbreaking advancements in oral formulation technologies.
This collaboration represents a significant step forward in the field of drug delivery, with the potential to transform the treatment landscape for chronic diseases by making peptide therapies more accessible and effective for patients worldwide.
Curated from Reportable
